http://www.cnr.it/ontology/cnr/individuo/prodotto/ID12096
Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production (Articolo in rivista)
- Type
- Label
- Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production (Articolo in rivista) (literal)
- Anno
- 2006-01-01T00:00:00+01:00 (literal)
- Alternative label
Poma P., Notarbartolo M., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano, Cervello M.,D'Alessandro N. (2006)
Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production
in International journal of oncology
(literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
- Poma P., Notarbartolo M., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano, Cervello M.,D'Alessandro N. (literal)
- Pagina inizio
- Pagina fine
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
- Rivista
- Note
- ISI Web of Science (WOS) (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
- Dipartimento di Scienze Farmacologiche, Universita di Palermo, Via del Vespro 129, I-90127 Palermo;
IBIM C.N.R. 'Alberto Monroy', Via U. La Malfa 153, I-90146 Palermo, Italy (literal)
- Titolo
- Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production (literal)
- Abstract
- We tested the novel NF-kB inhibitor dehydroxymethylepoxyquinomicin
(DHMEQ) in the hepatic cancer
(HCC) HepG2, HA22T/VGH and HuH-6 cells. The sensitivity
to the cell growth inhibitory and apoptotic effects of the
agent increased along with the levels of constitutively activated
NF-?B, which were low in HepG2 and higher in HA22T/VGH
and HuH-6. In HA22T/VGH, DHMEQ exhibited synergy with
cisplatin. In the same cells, DHMEQ exerted dose-dependent
decreases in the nuclear levels of activated NF-kB and
attenuated NF-?B activation by cisplatin. It down-regulated
Bcl-XL mRNA in a dose-dependent manner and up-regulated
that of Bcl-XS. It also decreased interleukin 6 (IL-6), NAIP
and, after 16 h of exposure to the higher concentration
tested (10 ug/ml), c-IAP-1 mRNA levels. At 10 ?g/ml it
caused significant increase in Bax, XIAP, cyclin D1 and ßcatenin
mRNAs. The combination of DHMEQ with cisplatin
produced unexpected significant decrease in c-IAP-2 and
Bcl-XS mRNAs as well as additive decrease (IL-6, NAIP
and, after 16 h, Bcl-XL) or increase (XIAP at 8 h) in gene
expression. HA22T/VGH produce IL-6; in agreement with
the results on mRNA, DHMEQ inhibited such a process.
HA22T/VGH lack the IL-6 receptor alpha chain, ruling out
that in these cells the antitumor effects of DHMEQ may be
attributed to an interference with a growth stimulatory
autocrine loop based on IL-6. However, the use of DHMEQ
in HCC might be beneficial to contrast the adverse systemic
effects of the released cytokine. (literal)
- Prodotto di
- Autore CNR
Incoming links:
- Autore CNR di
- Prodotto
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi